OClawVPS.com
Morrow Sodali
Edit

Morrow Sodali

https://morrowsodali.com/
Last activity: 29.05.2025
Active
Categories: AssistedCloudCorporateFinTechFirmGrowthMarketMessangerProviderService
Morrow Sodali is a leading provider of strategic advice and shareholder services to corporate clients around the world.

The firm provides corporate boards and executives with strategic advice and services relating to corporate governance, shareholder and bondholder communication and engagement, capital markets intelligence, proxy solicitation, shareholder activism and mergers and acquisitions.

From headquarters in New York and London, and offices and partners in major capital markets, Morrow Sodali serves more than 700 corporate clients in 40 countries, including many of the world’s largest multinational corporations. In addition to listed and private companies, its clients include mutual funds, ETFs, stock exchanges and membership associations.
Followers
928
Followers
13.83K
Website visits
34.9K /mo.
Mentions
30
Location: United States, New York
Employees: 201-500
Founded date: 1972

Investors 1

DateNameWebsite
06.11.2023St. Cloud ...stcloudcap...

Mentions in press and media 30

DateTitleDescription
29.05.2025First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CTSYDNEY, May 29, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment out...
20.05.2025Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commencesSYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment out...
17.04.2025Advancements in Cancer Treatment: A New Dawn for Prostate and Brain Cancer TherapiesIn the ever-evolving landscape of cancer treatment, two recent studies shine a light on innovative therapies that could reshape patient outcomes. The SECuRE trial, focusing on prostate cancer, and the IPAX-Linz study, targeting gliomas, are...
17.04.2025Clarity signs high-volume commercial-scale copper-64 Supply Agreement with NusanoHighlights Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or 64Cu) isotope. The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing mor...
15.04.2025SECuRE trial update: First patient treated in the Phase II Cohort ExpansionHIGHLIGHTS The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review...
10.03.2025Promising Advances in Cancer Treatment: A Look at Recent Developments in Glioblastoma and Prostate Cancer TherapiesIn the ever-evolving landscape of cancer treatment, two recent developments stand out: the collaboration between DBP International AB and Vivo Biopharma LLC on SI-053, and the SECuRE trial's promising results for 67Cu-SAR-bisPSMA. Both init...
05.03.2025SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.HIGHLIGHTS Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study. Based on the efficacy and safety assessment of all cohorts and t...
19.02.2025Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMASYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou...
24.01.2025Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancerSYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment ou...
22.08.2024Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMASYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In